Galecto is a clinical stage biotechnology company committed to the development of novel small molecule therapeutics directed at biological targets which are at the heart of fibrosis, inflammation, and cancer.
Galecto was founded by leading fibrosis-focused scientists and biotech executives and is built on more than 10 years of research into galectin and fibrosis modulators. Our team has developed a deep understanding of the galectin family of proteins and the LOXL2 enzyme, and how both influence multiple biological pathways of these complex, often devastating, diseases.
Galecto is funded by Novo Holdings, OrbiMed, Ysios, HBM Healthcare Investments, Sunstone Capital, M Ventures, Bristol-Myers Squibb, Maverick Ventures, Seventure and SEED Capital.
Company Details
- Employees
- 17
- Founded
- -
- Address
- Copenhagen, Dk
- hs****@****cto.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.galecto.com
- Keywords
- Galectin modulators, Galectin-3 inhibitors, Fibrosis treatment, LOXL2, Inflammation, Oncology, IPF, Liver fibrosis, Myelofibrosis.
- HQ
- Copenhagen, DK
Galecto, Inc. Questions
Galecto, Inc.'s website is http://www.galecto.com
Galecto, Inc.'s LinkedIn profile is https://dk.linkedin.com/company/galecto-biotech
Galecto, Inc. has
17 employees.
View email and phone details for 17
employees at Galecto, Inc..
Galecto, Inc.'s industry is
Biotechnology Research
Galecto, Inc.'s top competitors are
Bridge Medicines Llc,
Hoba Therapeutics,
Evaxion A/s,
Acesion Pharma,
Alentis Therapeutics,
Io Biotech,
Rivus Pharmaceuticals,
Zealand Pharma,
Genmab,
Adcendo.
Galecto, Inc.'s support email address is hs@galecto.com
Galecto, Inc.'s categories are Biotechnology Research
Galecto, Inc.'s founding year is 2011
